NCT05090449View on ClinicalTrials.gov

Non-interaction Study of Chlorthalidone and Losartan in Fixed Combination, in Healthy Subjects, Under Fasting Conditions

PHASE1CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

May 1, 2019

Primary Completion Date

April 8, 2020

Study Completion Date

May 25, 2020

Conditions
Healthy
Interventions
DRUG

Chlorthalidone (HIGROTON® 50)

Tablets with 50mg of Chlorthalidone, product de Sandoz, S.A. de C.V.

DRUG

Losartan (COZZAR®)

Losartan potassium 100 mg tablet, a product of Schering-Plough, S.A. C.V.

DRUG

A1+ A2 Co-administration of Chlorthalidone and Losartan

50mg chlorthalidone + 100 mg losartan potassium

DRUG

Chlorthalidone + Losartan Fixed-Dose combination

Tablets with fixed combination of Chlorthalidone 25 mg and Losartan Potassium

Trial Locations (1)

11000

Laboratorio Silanes, S.A. de C.V., Mexico City

All Listed Sponsors
lead

Laboratorios Silanes S.A. de C.V.

INDUSTRY

NCT05090449 - Non-interaction Study of Chlorthalidone and Losartan in Fixed Combination, in Healthy Subjects, Under Fasting Conditions | Biotech Hunter | Biotech Hunter